Related Experiment Video
Updated: Jun 16, 2026

13:05
Micropatterning and Assembly of 3D Microvessels
Published on: September 9, 2016
Harnessing systems biology approaches to engineer functional microvascular networks
Lauren S Sefcik1, Jennifer L Wilson, Jason A Papin
1Department of Chemical and Biomolecular Engineering, Lafayette College, Easton, Pennsylvania, USA.
Tissue Engineering. Part B, Reviews
|February 4, 2010
Summary
Systems biology offers a new approach to understanding blood vessel growth (angiogenesis). Analyzing gene networks can improve the discovery of new pro-angiogenic drugs and reduce clinical trial failures.
Area of Science:
- Cardiovascular Biology
- Systems Biology
- Drug Discovery
Background:
- Microvascular remodeling involves complex cell and molecular signaling.
- Many pro-angiogenic drug candidates fail in clinical trials, often due to single-target approaches.
- Understanding coordinated gene networks is crucial for effective therapeutic development.
Purpose of the Study:
- To review the application of systems biology to microvascular growth and remodeling.
- To highlight the utility of network analysis in discovering novel pro-angiogenic drug targets.
- To explore how a systems approach can improve the success rate of pro-angiogenic therapies.
Main Methods:
- Integration of multi-omics data using systems biology principles.
- Network analysis to identify key regulators and interactions in angiogenesis.
- Review of existing literature on systems biology applications in vascular biology.
Main Results:
- Systems biology provides a holistic network view of angiogenesis and arteriogenesis.
- Network analysis can predict potential drug targets and treatment outcomes.
- A systems approach offers a more comprehensive understanding than single-molecule studies.
Conclusions:
- Systems biology and network analysis are powerful tools for understanding microvascular remodeling.
- This approach can enhance the discovery and development of effective pro-angiogenic drugs.
- Moving beyond single targets to network-level interventions may reduce clinical trial attrition.

